Asone (N = 51) Male sex--n Age--years Height (cm) Actual physique weight (kgAsone (N

Asone (N = 51) Male sex–n Age–years Height (cm) Actual physique weight (kg
Asone (N = 51) Male sex–n Age–years Height (cm) Actual body weight (kg) Physique mass index (kg/m2 ) 44 (86.3) 58 9 172 7 82 16 27.7 5.3 67 6 26 6 five [3; 7] 2 [2; 2] Methylprednisolone (N = 29) 24 (82.eight) 64 9 173 eight 80 18 26.eight 5.2 67 6 28 eight three [2; 4] 2 [2; 3] p 0.6720 0.0154 0.7017 0.6178 0.4522 0.7249 0.2515 0.0057 0.Predicted body weight (kg) SAPS II score SOFA score Frailty score Comorbidities–n Hypertension Diabetes Obesity COPD Duration of symptoms before hospitalization (days) CPAP just before ICU admission–n Prone position through CPAP–n Duration of CPAP prior to BMS-8 Cancer intubation (days) Prone positioning for the duration of ICU stay–n Tracheostomy–n Administration of tocilizumab–n 17 (33.3) six (11.eight) 14 (27.5) three (five.9) 7 [5; 10] 47 (92.two) 24 (47.1) two [1; 4] 24 (47.0) 17 (33.3) 12 (23.5)13 (44.8) four (13.8) 4 (13.8) 1 (three.four) 7 [5; 10] 25 (86.2) 13 (44.eight) 3 [1; 6] 10 (34.five) 9 (31.0) 10 (34.5)0.3101 0.7982 0.1545 0.0990 0.6324 0.3945 0.8471 0.1232 0.274 0.8330 0.J. Clin. Med. 2021, ten,6 ofTable 1. Cont. Dexamethasone (N = 51) Biochemistry at ICU admission Procalcitonin ( /L) C-reactive protein (mg/L) Fibrinogen (mg/100 mL) D-dimer (ng/mL) Haemoglobin (g/dL) Platelet count (1/mm3 ) White blood cell (1/mm3 ) Creatinine (mg/dL) Bilirubin (mg/dL) Interleukin-6 (ng/L) Mechanical ventilation and gas exchange at ICU admission Respiratory method compliance (ml/cmH2 O) Airway driving stress (cmH2 O) Airway plateau stress (cmH2 O) PEEP (cmH2 O) Tidal volume (mL) Tidal volume (mL/kg abw) Respiratory rate (1/min) FiO2 pH PaO2 (mmHg) PaCO2 (mmHg) PaO2 /FiO2 (mmHg) Ventilatory ratio 50.eight 15.6 10 [8; 12] 24 [22; 26] 14 [14; 15] 492 53 7.four 0.9 20 3 70.9 13.5 7.36 0.09 129.six 46.9 51.2 12.eight 188.6 75.1 1.9 [1.5; two.3] 47.6 14.four 11 [9; 13] 24 [23; 28] 14 [13; 15] 491 52 7.4 0.7 19 three 69.six 17.7 7.37 0.07 135.6 59.eight 46.2 eight.five 201.3 74.5 1.six [1.3; two.0] 0.3884 0.1734 0.7076 0.1281 0.9457 0.9191 0.5045 0.7247 0.5994 0.6314 0.0777 0.4863 0.0451 0.53 [0.21; 1.12] 17.4 [10.9; 24.9] 680 [610; 770] 2270 [813; 4085] 11.four 1.9 278,156 11,3686 9709 4212 0.83 0.37 0.72 [0.49; 1.14] 88 [8; 198] 0.26 [0.13; 0.53] 12.1 [6.3; 17.1] 660 [514; 747] 1225 [712; 5051] 11.two 1.7 263,714 88,567 8429 3605 0.86 0.32 0.55 [0.39; 0.72] 78 [26; 159] 0.0445 0.0084 0.5111 0.6794 0.6765 0.5625 0.1786 0.8162 0.0334 0.9176 Methylprednisolone (N = 29) pSAPS II: simplified acute physiology score 2nd version; SOFA: sequential organ failure assessment; COPD: chronic obstructive pulmonary disease; CPAP: continuous optimistic airway pressure; ICU: intensive care unit; PEEP: positive end-expiratory pressure; FiO2 : fraction of inspired oxygen.Supplementary Table S2 shows the segmented regression for the analysis with the length of ICU keep through the weeks in which dexamethasone and methylprednisolone have been made use of. No differences had been identified in either the slope or the intercept from the regression curves among the two periods (p = 0.786 and p = 0.361, respectively). The outcomes in the dexamethasone vs. methylprednisolone comparison are shown in Table two. Even just after correction for the baseline imbalances, no statistically important variations in hospital mortality or in the duration of mechanical ventilation, the length of ICU remain, or the proportion of subjects who developed infectious complications were identified. A larger number of ventilator-associated pneumonia events per subjects and also a GNF6702 Parasite longer length of hospital keep were found in subjects who received methylprednisolone.J. Clin. Med. 2021, ten,7 ofTable two. Comparison of th.